 |
Journal articles
Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report
Résumé : Rituximab, an anti-CD20 monoclonal antibody, is an effective treatment for rheumatoid arthritis. Here
we report the case of a patient with rheumatoid arthritis, having taken risedronate for 14 months to
prevent corticosteroid-induced osteoporosis, more than 2 years ago, who presented osteonecrosis of jaw
following herpetic gingivostomatitis two weeks after the beginning of a rituximab treatment associated
with her usual anti-rheumatic drugs. Eight weeks later, no bone and/or gum healing was observed and a
stage 2 medication-related osteonecrosis of the jaw (MRONJ) was diagnosed. A conservative approach
was decided with antiseptic mouth washes, low-level laser treatment (LLLT) and systemic therapy with
teriparatide. Complete mucosal coverage was obtained after more two years of follow-up. We suggest
that rituximab as immunosuppressant might be a cause or a decompensating factor of MRONJ. Non-
surgical periodontal treatment with LLLT and teriparatide are candidates for the treatment of MRONJ.
https://hal.univ-reims.fr/hal-03579089
Contributor : Marius Colin Connect in order to contact the contributor
Submitted on : Thursday, February 17, 2022 - 6:09:55 PM
Last modification on : Friday, February 25, 2022 - 11:36:05 AM
Contributor : Marius Colin Connect in order to contact the contributor
Submitted on : Thursday, February 17, 2022 - 6:09:55 PM
Last modification on : Friday, February 25, 2022 - 11:36:05 AM